JHJD: JinHuangJieDu Formula SARS-CoV-2 Inhibition Data

375 ingredients and 338 target genes from a network pharmacology analysis of the JinHuangJieDu (JHJD) Traditional Chinese Medicine formula. The data, uploaded by Zhan-Qun Yang on figshare in May 2026, supports a study showing JHJD blocks SARS-CoV-2 RBD-ACE2 binding and modulates HIF-1α-dependent inflammation.

Use Cases

• Identifying potential drug candidates based on the 375 active ingredients listed.
• Analyzing pathway enrichment using the 63 significant pathways related to viral infection and inflammation.
• Validating predicted drug targets, such as CCND1 and HIF1A, in computational models.
• Comparing the inhibitory efficacy of JHJD against wildtype and Omicron SARS-CoV-2 variants.

Strengths

• Includes data on 375 active ingredients and 338 target genes from network pharmacology.
• Validates key findings with in vitro assays, confirming disruption of RBD-ACE2 binding.
• Released under a permissive CC-BY-4.0 license for open reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 20.0 KB file size suggests a limited scope, likely containing summary results rather than raw experimental data.

Provenance

Source

Zhan-Qun Yang via figshare.

Collection Method

Likely contains results from in vitro assays and computational network pharmacology analyses.

Freshness

Last updated 2026-05-11 05:28:56; freshness should be verified.